Gilead Sciences, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $28.65B | $18.20B | $6.00B |
| FY2021 | $25.18B | $21.07B | $5.34B |
| FY2022 | $22.96B | $21.24B | $5.41B |
| FY2023 | $23.19B | $22.83B | $6.09B |
| FY2024 | $24.90B | $19.33B | $9.99B |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $28.65B | $18.20B | $6.00B |
| FY2021 | $25.18B | $21.07B | $5.34B |
| FY2022 | $22.96B | $21.24B | $5.41B |
| FY2023 | $23.19B | $22.83B | $6.09B |
| FY2024 | $24.90B | $19.33B | $9.99B |